Drug eruption induced by IL-6 receptor inhibitor tocilizumab

Journal of the European Academy of Dermatology and Venereology

Volumn 24, Issue 4, 2010, Pages 495-496

  Yoshiki, R ^a   Nakamura, M ^a   Tokura, Y ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TOCILIZUMAB;

ADULT; ANAMNESIS; CASE REPORT; DRUG ERUPTION; HUMAN; LETTER; MALE; MEDICAL EXAMINATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SKIN BIOPSY;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; DRUG ERUPTIONS; HUMANS; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-6;

EID: 77749262178     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2009.03437.x     Document Type: Letter

References (10)

1. Saato K, Tsuchiyama M, Saldanha J et al. Resharping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 1993 53 : 851 856.
2. Nishimoto N, Yoshizaki K, Maeda K et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol 2003 30 : 1426 1435.
3. Nishimoto N, Yoshizaki K, Miyasaka N et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004 50 : 1761 1769.
4. Yokota S, Imagawa T, Mori M et al. Phase II trial of anti-IL-6 receptor antibody (MRA) for systemic onset juvenle idiopathic arthritis. Autoimmun Rev 2004 3 : 599 600.
5. Nishimoto N, Kanakura Y, Aozasa K et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005 106 : 2627 2632. (Pubitemid 41510733)
6. Ito H, Takazoe M, Fukuda Y et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004 126 : 989 996.
7. Maini RN, Tayler PC, Szechinski J et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006 54 : 2817 2829.
8. Stumber D, Awada A, Hirte H et al. Pooled safety analysis of BAY-43-9006 (Sorafenib) monotherapy in patients with advanced solid tumors: Is rash associated with treatment outcome? Eur J Cancer 2006 42 : 548 556.
9. Van Doorn R, Kirtschig G, Scheffer E et al. Follicular and epidermal alterations in patients treated with ZD 1839 (Iressa), and inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002 147 : 598 601.
10. Nakamura M, Tokura Y. Tocilizumab-induced erythroderma. Eur J Dermatol 2009 19 : 273 274.